Olympus (OTCMKTS:OCPNY) Stock Price Crosses Below 200-Day Moving Average – Here’s Why

Olympus Co. (OTCMKTS:OCPNYGet Free Report)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $18.00 and traded as low as $18.00. Olympus shares last traded at $18.00, with a volume of 400 shares changing hands.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised Olympus to a “buy” rating in a research report on Monday, May 18th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy”.

Read Our Latest Stock Report on OCPNY

Olympus Stock Performance

The stock has a market cap of $23.15 billion, a PE ratio of 21.95, a P/E/G ratio of 1.07 and a beta of 0.70. The business’s fifty day moving average price is $18.00 and its 200-day moving average price is $18.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.48 and a current ratio of 1.99.

About Olympus

(Get Free Report)

Olympus Corporation is a Tokyo-headquartered manufacturer specializing in medical and scientific imaging, precision optics and related equipment. The company’s medical systems business is focused on endoscopic technologies and therapeutic devices used in minimally invasive diagnosis and treatment, supplying hospitals and clinical facilities with endoscopes, visualization platforms and accessories. In addition to healthcare, Olympus serves scientific and industrial customers with microscopes, imaging systems, non-destructive testing equipment and precision measurement tools used in research, manufacturing and quality control.

In recent years the company completed a strategic refocus on healthcare and scientific solutions, divesting its consumer camera business in 2020 to concentrate resources on medical device development, services and life-science applications.

Read More

Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.